炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 每经记者｜王海慜 每经编辑｜赵云 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的 连续七天新春专题路演，到中信证券聚焦AI（人工智能）大模型的系列电话会，再到多家机构跟踪春 节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能 概念股表现亮眼。2月23日，港股大涨。截至收盘，恒生指数涨2.53%，恒生科技指数涨3.34%。 此外，业内预计，美国最高法院关税裁定利好非美市场资产，叠加A股春节效应的历史正向表现，市场 对马年春节后"红包行情"的延续抱有较高期待。 机器人、创新药大热 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、2026年十大产业趋势、全球估值比较、 全球产业映射、出海深度报告等多个维度。张启尧及其团队试图在春节假期这一A股市场"空窗期"，通 过高频的观点输出，抢占投资者的注意力高地。 这并非行业个例。多家机构 ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novo Nordisk slump wipes out last Wegovy-era gains after trial setback February 23, 202611:43 AM UTCUpdated ago By Reuters The logo of pharmaceutical company Novo Nordisk is displayed on a flag in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little Purchase Licensing Rights, opens new tab Feb 23 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab shares ...

Summary of Novo Nordisk Conference Call Company and Industry - **Company**: Novo Nordisk - **Industry**: Pharmaceutical, specifically focusing on obesity treatments and GLP-1 receptor agonists Key Points and Arguments REDEFINE 4 Trial Results - The REDEFINE 4 trial was an open-label study comparing the efficacy and safety of **CagriSema 2.4 mg** to **Tirzepatide 15 mg** in approximately **800** participants with obesity and comorbidities [4][5] - CagriSema achieved a **23%** reduction in body weight after **84 weeks**, while Tirzepatide resulted in a **25.5%** weight loss, failing to meet the primary endpoint of non-inferiority [5][6] - The trial was extended to **84 weeks** based on learnings from REDEFINE 1, but not all optimizations were implemented [4][6] Safety and Tolerability - The safety profile of CagriSema was consistent with previous trials, with gastrointestinal issues being the most common adverse events, generally mild to moderate [6] - The open-label design may have introduced bias favoring Tirzepatide, as many investigators were familiar with it, potentially affecting dosing adherence [6][27] Future Trials and Developments - CagriSema was submitted to the **FDA** for obesity treatment in **December 2025**, with a decision expected later this year [7] - The REDEFINE 11 trial is anticipated to explore the full weight loss potential of CagriSema, with results expected in the first half of **2027** [7][8] - Plans to initiate a Phase 3 trial for a high-dose CagriSema in the second half of **2026** were mentioned [8] Product Differentiation and Market Strategy - CagriSema aims to build upon the **Wegovy** brand, offering multiple treatment options for weight loss, including the recently launched **Wegovy pill**, which has shown a weight loss of close to **17%** [9][10] - The high-dose Wegovy is approved in the EU and UK, with a US decision expected by the end of Q1 [10] - Novo Nordisk is also advancing next-generation obesity treatments, including **zenagamtide**, which showed up to **24%** weight loss in Phase 2 trials [10][11] Competitive Landscape - The company believes CagriSema has the best weight loss efficacy compared to current market offerings, despite the recent trial results [36] - Concerns were raised about CagriSema's competitiveness against high-dose semaglutide and Tirzepatide, but the company maintains confidence in its product's unique benefits [57][59] Research and Development Insights - The company is leveraging insights from the REDEFINE program to enhance future trials, including the **AMAZE** program for zenagamtide [11][59] - There are ongoing discussions about the potential for additional head-to-head studies based on the outcomes of REDEFINE 11 [44][75] Other Important Content - The call included a Q&A session where analysts inquired about trial methodologies, dosing discrepancies, and the implications of the trial results on future product positioning [12][14][21][48] - The open-label nature of the REDEFINE 4 trial was highlighted as a significant factor that could have influenced the results, emphasizing the need for blinded studies in future comparisons [27][75]

Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial. ...

Core Viewpoint - Merck is restructuring its human-health business into two divisions to mitigate the impact of the impending patent loss of its leading drug, Keytruda [1] Group 1: Business Restructuring - Merck will create a separate division for its cancer drugs, which will include Keytruda [1] - The other division will focus on non-cancer products [1] Group 2: Market Context - The restructuring is a strategic response to the pressures associated with the patent expiration of Keytruda, which is Merck's top-selling drug [1]

Core Viewpoint - The drugmaker is restructuring its pharmaceuticals unit to enhance product launches ahead of a significant patent expiration [1] Group 1 - The company aims to bolster its product pipeline in anticipation of losing a crucial patent [1] - This strategic move is expected to improve the company's competitive position in the market [1] - The split of the pharmaceuticals unit is part of a broader strategy to optimize operations and focus on innovation [1]

Core Insights - The healthcare sector, particularly pharmaceutical and medical device companies, showed strong performance in the 2025 earnings season, outperforming the industry average [1][2] - Key companies discussed include Eli Lilly, AstraZeneca, Edwards Lifesciences, and Medtronic, highlighting significant revenue growth drivers [1] Sector Performance - The earnings reports reflect a backdrop of challenges such as geopolitical shifts, pricing pressures, and patent losses affecting the industry [2]

Core Viewpoint - Novo Nordisk's stock dropped 15% after its obesity drug CagriSema underperformed in a key trial compared to Eli Lilly's tirzepatide, raising concerns about its market position and future potential [1]. Group 1: Trial Results - CagriSema achieved an average weight loss of 20.2% after 84 weeks, while Lilly's tirzepatide resulted in 23.6% weight loss, indicating a significant performance gap [1]. - The trial missed its primary endpoint of demonstrating non-inferiority in weight loss compared to tirzepatide, marking a setback for Novo in the competitive obesity drug market [1]. Group 2: Market Impact - Following the trial results, Novo shares fell by as much as 15.4% in Copenhagen trading, while Lilly shares rose by 4.2% in premarket US trading, reflecting market disappointment in CagriSema's effectiveness [1]. - The results could limit CagriSema's commercial potential as Novo faces pressure to regain market share lost to Lilly's products [1]. Group 3: Strategic Importance - CagriSema is a central element of Novo's long-term obesity strategy, especially as patents for its existing drugs, Wegovy and Ozempic, approach expiry [1]. - The injection combines semaglutide with cagrilintide to enhance appetite suppression and improve weight-loss outcomes, but the trial results have raised doubts about its competitive edge [1]. Group 4: Management and Company Performance - The trial setback occurs amid significant internal changes at Novo, including a new CEO and board-level departures due to competitive performance concerns [1]. - Novo's market value has decreased to approximately $189 billion, down from a peak of over $600 billion in 2024, with shares falling more than 58% over the past year [1]. - The new CEO has announced job cuts and is actively seeking future obesity deals, indicating a strategic pivot in response to recent challenges [1].

Core Viewpoint - Shares of the Danish drugmaker fell sharply after the announcement that its CagriSema experimental obesity drug did not outperform Eli Lilly's Zepbound in a head-to-head clinical trial [1] Group 1 - The CagriSema drug is aimed at obesity treatment and was expected to compete with Eli Lilly's Zepbound [1] - The clinical trial results indicated that CagriSema failed to deliver better weight loss results compared to Zepbound [1] - The market reaction was negative, leading to a significant drop in the company's share price following the news [1]

Core Viewpoint - Novo Nordisk shares faced pressure due to a head-to-head study indicating that its drug in development was less effective in weight loss compared to a product from Eli Lilly [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company currently experiencing challenges with its drug development [1] - The company's recent study results have raised concerns about its competitive position in the market against Eli Lilly [1] Industry Summary - The pharmaceutical industry is witnessing intense competition, particularly in the weight loss drug segment, where efficacy is a critical factor for market success [1] - Eli Lilly's product has set a benchmark that other companies, including Novo Nordisk, must meet or exceed to remain competitive [1]